medAI Times Daily — Apr 28, 2026

India's biggest southern state just bought AI to find lung cancer.Run time: 21:45In today's episode:AstraZeneca and Qure.ai sign Telangana lung-cancer dealNovo Nordisk taps OpenAI for drug discoveryBerkeley and UCSF release Pillar imaging vision-language modelAmbient AI scribes ease burnout in pragmatic RCTUCSF collaborative quantifies real-world scribe time savingsDaiichi Sankyo partners with Imagene AI on oncology biomarkersMoffitt finds radiologists prefer domain-specific impression AIAnthropic launches nine creative-tool connectors including BlenderAnthropic ships Claude Design in research previewIsomorphic teases an AlphaFold-4-class drug discovery modelTL;DR:AstraZeneca and Qure.ai are scaling AI-powered lung-cancer screening across Telangana, India, signaling a population-health deployment template for the Global South.Two large studies of ambient AI scribes (a multi-site UCSF cohort and a Stanford-led pragmatic RCT) show real but modest EHR time savings and clearer burnout improvement only with frequent use.Anthropic widened Claude's creative-tools surface today with nine new MCP connectors (Blender, Adobe) and is pushing Claude Design into research preview.Sources cited:Qure.ai newsroomCNBCITN OnlineNEJM AISTATBioPharm InternationalRadiology BusinessYesil Science Digest9to5MacTechCrunchSubscribe: YouTubemedAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.